Correction: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma
Yao Liang, Osamu Maeda, Chiaki Kondo, Kazuki Nishida, Yuichi Ando
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLung Cancer Treatments and Mutations · Cancer Immunotherapy and Biomarkers · Lung Cancer Research Studies
There are errors in the author affiliations. The correct affiliations are as follows:
Yao Liang^1^, Osamu Maeda^2^, Chiaki Kondo^2^, Kazuki Nishida^3^, Yuichi Ando^2^
1 Division of Clinical Oncology and Chemotherapy, Department of Integrated Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, 2 Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan, 3 Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Liang Y, Maeda O, Kondo C, Nishida K, Ando Y. Effects of KRAS, STK 11, KEAP 1, and TP 53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. P Lo S One. 2024;19(7):e 0307580. doi: 10.1371/journal.pone.0307580 39037971 PMC 11262633 · doi ↗ · pubmed ↗